Loading clinical trials...
Loading clinical trials...
A Phase III, Randomized, Multi-Center, Double-Blind, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination With and Following Chemoradiotherapy Compared to Chemoradiotherapy Alone for Treatment in Women With Locally Advanced Cervical Cancer
Conditions
Interventions
Durvalumab
Cisplatin
+2 more
Locations
117
United States
Research Site
Phoenix, Arizona, United States
Research Site
La Jolla, California, United States
Research Site
Orange, California, United States
Research Site
Fort Myers, Florida, United States
Research Site
Miami, Florida, United States
Research Site
Augusta, Georgia, United States
Start Date
February 15, 2019
Primary Completion Date
January 20, 2022
Completion Date
July 3, 2023
Last Updated
July 26, 2024
NCT05975593
NCT07104149
NCT06288373
NCT05687851
NCT05378087
NCT05950087
Lead Sponsor
AstraZeneca
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions